Dysregulated Expression of MiR-19b, MiR-25, MiR-17, WT1, and CEBPA in Patients with Acute Myeloid Leukemia and Association with Graft versus Host Disease after Hematopoietic Stem Cell Transplantation

Mahdiyar Iravani Saadi; Fatemeh Tahmasebijaroubi; Esmat Noshadi; Raha Rahimikian; Zahed Karimi; Maryam Owjfard; Ahmad Niknam; Ehsan Nabi Abdolyousefi; Sanaz Salek; Reza Tabrizi; Elham Jamali

doi:10.1055/s-0042-1742593

Dysregulated Expression of MiR-19b, MiR-25, MiR-17, WT1, and CEBPA in Patients with Acute Myeloid Leukemia and Association with Graft versus Host Disease after Hematopoietic Stem Cell Transplantation

South Asian J Cancer. 2022 Apr 25;11(4):346-352. doi: 10.1055/s-0042-1742593. eCollection 2022 Oct.

Authors

Affiliations

¹ Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
² Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
³ Department of Biochemistry, Bushehr University of Medical Sciences, Bushehr, Iran.
⁴ Hematology and Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran.
⁵ Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
⁶ Shiraz University of Applied Science and Technology (UAST), Shiraz, Iran.
⁷ Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
⁸ Non Communicable Diseases Research Center (NCDC), Fasa University of Medical Sciences, Fasa, Iran.

Abstract

Elham JamaliObjectives Acute myeloid leukemia (AML) is a blood malignancy characterized by the proliferation of aberrant cells in the bone marrow and blood that interfere with normal blood cells. We have investigated whether changes in the level of micro-ribonucleic acid (miR)-19b, miR-17, and miR-25, Wilms' tumor (WT1), and CCAAT enhancer-binding protein α (CEBPA) genes expression affect disease prognosis and clinical outcome in AML patients. Materials and Methods The expression level of miR-19-b, miR-17, and miR-25, as well as WT1 and CEBPA genes in a group of patients and controls as well as different risk groups (high, intermediate, and favorite risk), M3 versus non-M3, and graft-versus-host disease (GvHD) versus non-GvHD patients were assessed using a quantitative SYBR Green real-time polymerase chain reaction method. Results When compared with the baseline level at the period of diagnosis before chemotherapy, the expression of miR-19b and miR-17 in AML patients increased significantly after chemotherapy. The level of miR-19b and miR-25 expression in AML patients with M3 and non-M3 French-American-British subgroups differ significantly. MiR-19b and miR-25 expression was elevated in GvHD patients, while miR-19b and miR-25 expression was somewhat decreased in GvHD patients compared with non-GvHD patients, albeit the difference was not statistically significant. Also, patients with different cytogenetic aberrations had similar levels of miR-19-b and miR-25 expression. Conclusion MiR-19b, miR-17, and miR-25 are aberrantly expressed in AML patients' peripheral blood leukocytes, which may play a role in the development of acute GvHD following hematopoietic stem cell transplantation.

Keywords: acute graft versus host disease; acute myeloid leukemia; chemotherapy; microRNA; stem cell transplantation.

MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

Grants and funding

Funding Dr. Elham Jamali reports this work was financially supported by Shiraz University of Medical Sciences, Shiraz, Iran and grants from grant number 94–01–104–11279.